ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 11/07/22
Instil Bio Investigated by Block & Leviton for Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmNewsfile Corp • 11/03/22
ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 11/03/22
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 11/02/22
INSTIL BIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Instil Bio, Inc. on Behalf of Instil Bio Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 11/02/22
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of InvestorsBusiness Wire • 11/01/22
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of InvestorsBusiness Wire • 11/01/22
The Law Offices of Frank R. Cruz Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of InvestorsBusiness Wire • 11/01/22
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 11/01/22
EQUITY ALERT: Rosen Law Firm Encourages Instil Bio, Inc. Investors to Inquire About Securities Class Action Investigation – TILBusiness Wire • 10/31/22
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 10/31/22
Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trialsMarket Watch • 10/31/22
Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to ManufacturingGlobeNewsWire • 10/31/22
Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung CancerGlobeNewsWire • 10/18/22
Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/12/22
Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor MicroenvironmentGlobeNewsWire • 05/27/22
Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT)GlobeNewsWire • 05/18/22
Instil Bio Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/16/22
Instil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/07/22
Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/15/21